Toxoplasma gondii: The effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model

Experimental Parasitology

Volumn 133, Issue 3, 2013, Pages 294-299

  Martins Duarte, Érica S ^a,b   De Souza, Wanderley ^a,b,c   Vommaro, Rossiane C ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Inst Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens   (Brazil)

^c INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

AIDS; Azole; Drug interaction; Toxoplasmic encephalitis

Indexed keywords

FLUCONAZOLE; PYRIMETHAMINE; SULFADIAZINE;

ACUTE TOXOPLASMOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ACUTE DISEASE; ANIMALS; ANTIFUNGAL AGENTS; ANTIPROTOZOAL AGENTS; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; INHIBITORY CONCENTRATION 50; MACACA MULATTA; MICE; PYRIMETHAMINE; SULFADIAZINE; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

CANDIDA; FILOBASIDIELLA NEOFORMANS; MURINAE; MUS; TOXOPLASMA GONDII;

EID: 84872463692     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2012.12.011     Document Type: Article

References (29)

1. Anaissie E.J., Kontoyiannis D.P., Huls C., Vartivarian S.E., Karl C., Prince R.A., Bosso J., Bodey G.P. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J. Infect. Dis. 1995, 172:599-602.
2. Antinori A., Larussa D., Cingolani A., Lorenzini P., Bossolasco S., Finazzi M.G., Bongiovani M., et al. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin. Infect. Dis. 2004, 39:1681-1691.
3. Cavallito J.C., Nichol C.A., Brenckman W.D., Deangelis R.L., Stickney D.R., Simmons W.S., Sigel C.W. Lipid-soluble inhibitors of dihydrofolate reductase I Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metroprine, and etroprine in the rat, dog, and man. Drug. Metab. Dispos. 1978, 157:14-22.
4. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
5. Commodaro A.G., Belfort R.N., Rizzo L.V., Muccioli C., Silveira C., Burnier M.N., Belfort R. Ocular toxoplasmosis: an update and review of the literature. Mem. Inst. Oswaldo Cruz 2009, 104:345-350.
6. Foppa C.U., Bini T., Gregis G., Lazzarin A., Esposito R., Moroni M. A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. Eur. J. Clin. Microbiol. Infect. Dis. 1991, 10:187-189.
7. Fung H.B., Kirschenbaum H.L. Treatment regimens for patients with toxoplasmic encephalitis. Clin. Ther. 1996, 18:1037-1056.
8. Gubbins P.O., Amsden J.R. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin. Pharmacother. 2005, 6:2231-2243.
9. Harris C., Salgo M.P., Tanowitz H.B., Wittner M. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J. Infect. Dis. 1988, 157:14-22.
10. Hope W.W., Billaud E.M., Lestner J., Denning D.W. Therapeutic drug monitoring for triazoles. Curr. Opin. Infect. Dis. 2008, 21:580-586.
11. Katlama C., De Wit S., O'Doherty E., Van Glabeke M., Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin. Infect. Dis. 1996, 22:268-275.
12. Kiderlen T.R., Liesenfeld O., Schürmann D., Schneider T. Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART). Eur. J. Clin. Microbiol. Infect. Dis. 2011, 30:1521-1525.
13. Koltin Y., Hitchcock C.A. The search for new triazole antifungal agents. Curr. Opin. Chem. Biol. 1997, 1:176-182.
14. Lass-Flörl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs 2011, 71:2405-2419.
15. Li X.Q., Bjorkman A., Andersson T.B., Gustafsson L.L., Masimirembwa C.M. Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur. J. Clin. Pharmacol. 2003, 59:429-442.
16. Luft B.J., Remington J.S. AIDS commentary. Toxoplasmic encephalitis. J. Infect. Dis. 1988, 157:1-6.
17. Martins-Duarte, Edos S., de Souza W., Vommaro R.C. Itraconazole affects Toxoplasma gondii endodyogeny. FEMS Microbiol. Lett. 2008, 282:290-298.
18. Martins-Duarte E.S., Lemgruber L., de Souza W., Vommaro R.C. Toxoplasma gondii: fluconazole and itraconazole activity against toxoplasmosis in a murine model. Exp. Parasitol. 2010, 124:466-469.
19. Nobre V., Braga E., Rayes A., Serufo J.C., Godoy P., Nunes N., Antunes C.M., Lambertucci J.R. Opportunistic infections in patients with AIDS admitted to an university hospital of the southeast of Brazil. Rev. Inst. Med. Trop. Sao Paulo 2003, 45:69-74.
20. Nussbaum J.C., Jackson A., Namarika D., Phulusa J., Kenala J., Kanyemba C., Jarvis J.N., Jaffar S., Hosseinipour M.C., Kamwendo D., van der Horst C.M., Harrison T.S. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin. Infect. Dis. 2010, 50:338-344.
21. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 2003, 52:1.
22. Penna-Coutinho J., Cortopassi W.A., Oliveira A.A., França T.C., Krettli A.U. Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoS One 2011, 6:e21237.
23. Singer E.J., Valdes-Sueiras M., Commins D., Levine A. Neurologic presentations of AIDS. Neurol. Clin. 2010, 28:253-275.
24. Vidal J.E., Hernandez A.V., de Oliveira A.C., Dauar R.F., Barbosa S.P., Focaccia R. Cerebral toxoplasmosis in HIV positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care STDS 2005, 19:626-634.
25. Tallarida R.J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 2006, 319:1-7.
26. Thompson G.R., Patel P.K., Kirkpatrick W.R., Westbrook S.D., Berg D., Erlandsen J., Redding S.W., Patterson T.F. Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 2010, 109:488-495.
27. Voss A., De Pauw B.E. High-dose fluconazole therapy in patients with severe fungal infections. Eur. J. Clin. Microbiol. Infect. Dis. 1999, 18:165-174.
28. Wang J.L., Chang C.H., Young-Xu Y., Chan K.A. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob. Agents Chemother. 2010, 54:2409-2419.
29. Winter H.R., Unadkat J.D. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab. Dispos. 2005, 33:969-976.